




INTRODUCTION




Mannosylated LNPs Retain Stability and Enhance Transfection After 4 Weeks of Storage at 4°C






Successful endosomal escape



Mannosylated LNPs led to more cy5-positive DC2.4 cells




Mannosylated LNPs Preferentially deliver mRNA to lymph nodes



CONCLUSION

- Two amphiphilic lipids were successfully synthesized to incorporate mannose into LNP formulations.
- Mannosylated LNPs with narrow size distribution and high colloidal stability
- Mannosylated LNPs exhibited enhanced uptake in dendritic cells compared to ALC-LNPs.
- Mannosylated LNPs maintained physicochemical and mRNA transfection stability for up to one month, comparable to ALC-LNPs.
- Mannosylated LNPs demonstrated preferential accumulation in lymph nodes with minimal liver uptake.


DESIGN & METHODOLOGY



RESULTS & DISCUSSIONS

3 LNPs stood out after *in vitro* screening

35 different mole ratios were screened: varying component's mole ratios



Physicochemical properties of optimal LNPs after screening:

- Size: <130 nm
- Zeta potential: within ± 10 mV
- Encapsulation efficiency (EE): >85%

Mole Ratios	ALC0 315	DSPC	Chol	PEG	CM	CPSM
ALC	46.3	9.4	42.7	1.6	0	0
CM	32.7	0	11.6	0	0	0
CM/CPSM	Kept Constant	27.8	0	15.0	1.4	0
CPSM	42.7	0	0	0	1.4	0

REFERENCES

- H. Feinberg, S. A. F. Jégouzo, Y. Lasanajak, D. F. Smith, K. Drickamer, W. I. Weis, M. E. Taylor, *J. Biol. Chem.* **2021**, 296, 100368.
- J.-Y. Zeng, S. Linqesh, N. D/O B. Krishnan, B. Seow, M. Liu, Q. Chen, Y. Y. Yang, *Small Methods* **2025**, 2401712

ACKNOWLEDGEMENTS

This work was supported by the Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), IAF-PP (H22/Ja0050) and NRF-CRP (CRP27-2021-0038), Republic of Singapore.